Table 2.
Medical Management of Mast Cell Disorders.
Drug Class | Medication and Dosing | Primary Indication and Comments |
---|---|---|
H1-receptor
antagonist |
Long-acting:
Short-acting:
|
Histamine-related symptoms (i.e., flushing, pruritis) |
H2-receptor
antagonist |
Ranitidine (150 mg orally, twice/day) Famotidine (10 mg orally twice/day) |
Gastrointestinal symptoms |
Proton-Pump
Inhibitor (PPI) |
Omeprazole (20–40 mg orally daily Pantoprazole (20–40 mg orally daily) |
Gastrointestinal symptoms |
Leukotriene
receptor antagonist |
Montelukast (10 mg orally daily Zafirlukast (20 mg orally daily) |
Histamine-related symptoms (i.e., flushing, pruritis) |
Mast cell stabilizer | Cromolyn sodium (four times a day maximum daily dose 40 mg/kg/day) | Gastrointestinal symptoms Histamine-related symptoms (i.e., flushing, pruritis) |
Non-steroidal anti-inflammatory drug (NSAID) | Aspirin (variable dosing) | Histamine-related symptoms (i.e., flushing, pruritis) |
Anti-IgE
monoclonal antibody |
Omalizumab (150–300 mg administered subcutaneously every 2–4 weeks) | Histamine-related symptoms (i.e., flushing, pruritis, recurrent anaphylaxis) not responsive to conservative measures |
Immediate administration for anaphylaxis | Epinephrine (0.3–0.5 mg intramuscularly every 5–15 min in the lateral thigh) | Anaphylaxis |
Cytoreductive therapy | Interferon-α (IFN-α)
Cladribine (2-CdA)
|
IFN-α: often co-administer with prednisone to improve tolerability Flu-like syndrome 2-CdA: myelosuppression and lymphopenia common. Prophylaxis for Pneumocystis jirovecii infection needed |
Abbreviations: mg, milligrams; PO, per oral; BID, twice daily; PRN, as needed; QID, four times daily; kg, kilograms; SQ, subcutaneous; IM, intramuscular; MU, million units.